E S Antonarakis
Overview
Explore the profile of E S Antonarakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
605
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Scher H, Armstrong A, Schonhoft J, Gill A, Zhao J, Barnett E, et al.
Eur J Cancer
. 2021 Apr;
150:83-94.
PMID: 33894633
Purpose: To evaluate the prognostic significance of circulating tumour cell (CTC) number determined on the Epic Sciences platform in men with metastatic castration-resistant prostate cancer (mCRPC) treated with an androgen...
3.
Lu C, Terbuch A, Dolling D, Yu J, Wang H, Chen Y, et al.
Ann Oncol
. 2020 May;
31(9):1178-1185.
PMID: 32387417
Background: In men with castration-sensitive prostate cancer (CSPC), the HSD3B1 c.1245A>C variant has been reported to be associated with shorter responses to first-line androgen-deprivation therapy (ADT). Here, we evaluated the...
4.
Armstrong A, Antonarakis E, Taplin M, Kelly W, Beltran H, Fizazi K, et al.
Ann Oncol
. 2017 Nov;
29(1):23-25.
PMID: 29088323
No abstract available.
5.
Rathkopf D, Smith M, Ryan C, Berry W, Shore N, Liu G, et al.
Ann Oncol
. 2017 Jun;
28(9):2264-2271.
PMID: 28633425
Background: Mutations in the androgen receptor (AR) ligand-binding domain (LBD), such as F877L and T878A, have been associated with resistance to next-generation AR-directed therapies. ARN-509-001 was a phase I/II study...
6.
Benzon B, Zhao S, Haffner M, Takhar M, Erho N, Yousefi K, et al.
Prostate Cancer Prostatic Dis
. 2016 Nov;
20(1):28-35.
PMID: 27801901
Background: B7-H3 (CD276), part of the B7 superfamily of immune checkpoint molecules, has been shown to have an immunomodulatory role. Its regulation, receptor and mechanism of action remain unclear. B7-H3...
7.
Antonarakis E, Armstrong A, Dehm S, Luo J
Prostate Cancer Prostatic Dis
. 2016 May;
19(3):231-41.
PMID: 27184811
While there are myriad mechanisms of primary and acquired resistance to conventional and next-generation hormonal therapies in prostate cancer, the potential role of androgen receptor splice variants (AR-Vs) has recently...
8.
Teply B, Luber B, Denmeade S, Antonarakis E
Prostate Cancer Prostatic Dis
. 2016 Feb;
19(1):72-8.
PMID: 26857146
Background: Prednisone and other corticosteroids can provide palliation and tumor responses in patients with prostate cancer. The combination of docetaxel and prednisone was the first treatment shown to prolong survival...
9.
Nakazawa M, Lu C, Chen Y, Paller C, Carducci M, Eisenberger M, et al.
Ann Oncol
. 2015 Jun;
26(9):1859-1865.
PMID: 26117829
Background: We previously showed that pretreatment detection of androgen receptor splice variant-7 (AR-V7) in circulating tumor cells (CTCs) from men with castration-resistant prostate cancer is associated with resistance to abiraterone...
10.
Cheng H, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan U, et al.
Prostate Cancer Prostatic Dis
. 2015 Jan;
18(2):122-7.
PMID: 25600186
Background: Enzalutamide and abiraterone are new androgen-axis disrupting treatments for metastatic castration-resistant prostate cancer (mCRPC). We examined the response and outcomes of enzalutamide-treated mCRPC patients in the real-world context of...